drugset
Drugs / THEO-260
last change 17 days ago re-read 3 minutes ago

THEO-260

Other / unclassified

Developed for
ovarian cancer
Investigated by
Theolytics Limited

Trials 2

today NCT07211659 · Ph 1 NCT06618235 · Ph 1/2
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07211659 Feb 2026 → Sep 2027 expected ovarian cancer Theolytics Limited Recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT06618235 Sep 2024 → Jun 2028 expected ovarian cancer Theolytics Limited Recruiting No outcome recorded

Press releases naming this drug 8 releases

DateIssuerRelease
2026-09-16 Theolytics Limited Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy – including THEO-260 in Advanced Ovarian Cancer – at Upcoming Investor and Scientific Events theolytics.com ↗
2026-07-16 Theolytics Limited Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies theolytics.com ↗
2026-05-28 Theolytics Limited Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026 theolytics.com ↗
2026-04-28 Theolytics Limited Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer theolytics.com ↗
2026-03-04 Theolytics Limited Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer theolytics.com ↗
2025-10-13 Theolytics Limited Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025 in Berlin theolytics.com ↗
2024-11-19 Theolytics Limited Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer theolytics.com ↗
2023-06-09 Theolytics Limited Theolytics presents data on THEO-260 at ASCO and EHA theolytics.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as THEO-260 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06618235 ↗
1

NCT07211659 ↗
Modality Other / unclassified “Oncolytic virus” NCT07211659 ↗
Route Intravenous “THEO-260 administered intravenously” NCT06618235 ↗